華潤醫藥(03320.HK)2024年度營收2576.73億元，製藥業務及細分板塊均實現增長
格隆匯3月26日丨華潤醫藥(03320.HK)公佈年度業績，截至2024年12月31日止年度，集團錄得總收益達人民幣2576.733億元，較上年同期總收益人民幣2447.039億元增長5.3%。2024年製藥、醫藥分銷、藥品零售及其他三個主要業務分部的收益佔比分別為16.1%、80.0%以及3.9%。
報吿期內，集團實現毛利人民幣406.889億元，較2023年的毛利人民幣383.375億元增長6.1%。整體毛利率為15.8%，與2023年毛利率15.7%相比提高0.1個百分點，主要受益於報吿期內製藥業務毛利率水平提升拉動。
報吿期內，集團實現淨利潤人民幣84.032億元，較2023年的淨利潤人民幣77.750億元增長8.1%；實現公司擁有人應占溢利人民幣33.509億元，較2023年公司擁有人應占溢利人民幣38.542億元減少13.1%。剔除聯營公司減值等一次性項目影響，報吿期間內集團淨利潤同比穩健增長13.1%；公司擁有人應占溢利同比增長0.5%。報吿期間內每股基本盈利為人民幣0.53元。如剔除少數股東權益增加以及非經常性損益的影響，2024年公司擁有人應占溢利同比實現雙位數增長。董事會建議派付截至2024年12月31日年度的末期股息每股人民幣0.052元。
2024年集團製藥業務及細分板塊均實現增長，毛利率進一步提升，充分體現了高質量發展的良好態勢。報吿期內本集團着力加強中藥、化藥、生物製品全產業鏈建設，進一步發揮中藥產業鏈融通帶動作用；堅定推動創新轉型，通過自研+合作方式，獲得多項成果，創新能力得到進一步提升；打造卓越運營體系，主動開展降本增效，大力提升數字化和綠色低碳水平，獲得多項榮譽；加快外延發展，實現3個併購項目落地，引進多個產品，不斷豐富產品組合，推動對昆藥集團、綠十字的併購整合取得實效；主動應對集採，14個品種中選國家第十批集採。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
